These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 17052978)
1. The membrane-proximal region of the thrombopoietin receptor confers its high surface expression by JAK2-dependent and -independent mechanisms. Tong W; Sulahian R; Gross AW; Hendon N; Lodish HF; Huang LJ J Biol Chem; 2006 Dec; 281(50):38930-40. PubMed ID: 17052978 [TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Pecquet C; Diaconu CC; Staerk J; Girardot M; Marty C; Royer Y; Defour JP; Dusa A; Besancenot R; Giraudier S; Villeval JL; Knoops L; Courtoy PJ; Vainchenker W; Constantinescu SN Blood; 2012 May; 119(20):4625-35. PubMed ID: 22378845 [TBL] [Abstract][Full Text] [Related]
3. In and out: Traffic and dynamics of thrombopoietin receptor. Roy A; Shrivastva S; Naseer S J Cell Mol Med; 2021 Oct; 25(19):9073-9083. PubMed ID: 34448528 [TBL] [Abstract][Full Text] [Related]
6. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis. Ueda F; Tago K; Tamura H; Funakoshi-Tago M J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978 [TBL] [Abstract][Full Text] [Related]
7. Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo. Miura O; Nakamura N; Quelle FW; Witthuhn BA; Ihle JN; Aoki N Blood; 1994 Sep; 84(5):1501-7. PubMed ID: 8068943 [TBL] [Abstract][Full Text] [Related]
8. Modulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven activation from cytokine-induced stimulation. Papadopoulos N; Pristavec A; Nédélec A; Levy G; Staerk J; Constantinescu SN Blood; 2023 Nov; 142(21):1818-1830. PubMed ID: 37616564 [TBL] [Abstract][Full Text] [Related]
10. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Huang LJ; Constantinescu SN; Lodish HF Mol Cell; 2001 Dec; 8(6):1327-38. PubMed ID: 11779507 [TBL] [Abstract][Full Text] [Related]
11. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Staerk J; Lacout C; Sato T; Smith SO; Vainchenker W; Constantinescu SN Blood; 2006 Mar; 107(5):1864-71. PubMed ID: 16249382 [TBL] [Abstract][Full Text] [Related]
12. The extended box 2 subdomain of erythropoietin receptor is nonessential for Jak2 activation yet critical for efficient mitogenesis in FDC-ER cells. He TC; Jiang N; Zhuang H; Quelle DE; Wojchowski DM J Biol Chem; 1994 Jul; 269(28):18291-4. PubMed ID: 8034573 [TBL] [Abstract][Full Text] [Related]
13. A Phenotypic Screen for Small-Molecule Inhibitors of Constitutively Active Mutant Thrombopoietin Receptor Implicated in Myeloproliferative Neoplasms. Ngo A; Koay AZ; Pecquet C; Diaconu CC; Ould-Amer Y; Huang Q; Kang C; Poulsen A; Lee MA; Jenkins D; Shiau A; Constantinescu SN; Choong ML Comb Chem High Throughput Screen; 2016; 19(10):824-833. PubMed ID: 27748177 [TBL] [Abstract][Full Text] [Related]
14. Studies with chimeric Mpl/JAK2 receptors indicate that both JAK2 and the membrane-proximal domain of Mpl are required for cellular proliferation. Drachman JG; Miyakawa Y; Luthi JN; Dahlen DD; Raney A; Geddis AE; Kaushansky K J Biol Chem; 2002 Jun; 277(26):23544-53. PubMed ID: 11980901 [TBL] [Abstract][Full Text] [Related]
15. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Pecquet C; Staerk J; Chaligné R; Goss V; Lee KA; Zhang X; Rush J; Van Hees J; Poirel HA; Scheiff JM; Vainchenker W; Giraudier S; Polakiewicz RD; Constantinescu SN Blood; 2010 Feb; 115(5):1037-48. PubMed ID: 19996410 [TBL] [Abstract][Full Text] [Related]
16. The BRISC deubiquitinating enzyme complex limits hematopoietic stem cell expansion by regulating JAK2 K63-ubiquitination. Donaghy R; Han X; Rozenova K; Lv K; Jiang Q; Doepner M; Greenberg RA; Tong W Blood; 2019 Apr; 133(14):1560-1571. PubMed ID: 30755420 [TBL] [Abstract][Full Text] [Related]
17. Phospho-PTM proteomic discovery of novel EPO- modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 Signaling. Held MA; Greenfest-Allen E; Su S; Stoeckert CJ; Stokes MP; Wojchowski DM Cell Signal; 2020 May; 69():109554. PubMed ID: 32027948 [TBL] [Abstract][Full Text] [Related]
18. Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. Defour JP; Itaya M; Gryshkova V; Brett IC; Pecquet C; Sato T; Smith SO; Constantinescu SN Proc Natl Acad Sci U S A; 2013 Feb; 110(7):2540-5. PubMed ID: 23359689 [TBL] [Abstract][Full Text] [Related]
19. Calmodulin physically interacts with the erythropoietin receptor and enhances Jak2-mediated signaling. Kakihana K; Yamamoto M; Iiyama M; Miura O Biochem Biophys Res Commun; 2005 Sep; 335(2):424-31. PubMed ID: 16084495 [TBL] [Abstract][Full Text] [Related]
20. Two domains of the erythropoietin receptor are sufficient for Jak2 binding/activation and function. Pelletier S; Gingras S; Funakoshi-Tago M; Howell S; Ihle JN Mol Cell Biol; 2006 Nov; 26(22):8527-38. PubMed ID: 16982687 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]